A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19

Ren, Yunzhao R.; Golding, Amit; Sorbello, Alfred; Ji, Ping; Chen, Jianmeng; Saluja, Bhawana; Witzmann, Kimberly; Arya, Vikram; Reynolds, Kellie S.; Choi, Sang Hyoun; Nikolov, Nikolay P.; Sahajwalla, Chandrahas

doi:10.1002/jcph.1673

Cited by 17 publications

(17 citation statements)

References 186 publications

(237 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…More research is needed to determine when and for which patients, tocilizumab should be administered. 78,79 Based on recent data, tocilizumab can be considered in patients with extensive lung involvement and severe or critical patients with high IL-6 levels. Intravenous tocilizumab should be diluted to 100 mL with 0.9% normal saline, and the infusion time is at least 1 hour.…”

Section: Tocilizumab Potential For Use Efficacy In Covid-19 Based Onmentioning

confidence: 99%

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Khiali

Khani

Entezari‐Maleki

2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

Currently,the world is facing the pandemic of a novel strain of beta-coronavirus known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Acute respiratory distress syndrome (ARDS) is the most devastating complication of SARS-CoV-2. It was indicated that cytokine-release syndrome and dominantly interleukin (IL)-6 play a central role in the pathophysiology of ARDS related to the novel 2019 coronavirus disease (COVID-19). Despite the global emergency of the disease, at this time, there are no proven therapies for the management of the disease. Tocilizumab is a potential recombinant monoclonal antibody against IL-6 and currently is under investigation for the management of ARDS in patients with COVID-19. Given these points, we reviewed the current evidence regarding the potential therapeutic role of tocilizumab and its important clinical issues in the treatment of ARDS related to COVID-19.

show abstract

Section: Tocilizumab Potential For Use Efficacy In Covid-19 Based Onmentioning

confidence: 99%

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Khiali

Khani

Entezari‐Maleki

2020

The Journal of Clinical Pharma

View full text Add to dashboard Cite

show abstract

“…The WHO has issued guidelines for the protection of health care workers (HCWs) which recommend contact and droplet precautions during suspected COVID-19 patient support [10] and the US Center for Disease Control (CDC) implemented these guidelines adding the constant use of a face mask (e.g., surgical masks, FFP-2, FFP-3, KN95) to gain source control [11][12][13].…”

Section: Introductionmentioning

confidence: 99%

Impact of lockdown for SARS-CoV-2 (COVID-19) on surgical site infection rates: a monocentric observational cohort study

et al. 2020

View full text Add to dashboard Cite

show abstract

“…SARS-CoV-2 infection has spread extensively throughout the world and remains a formidable challenge for clinical testing. SARS-CoV-2 is a positive sense single stranded RNA virus that belongs to the β-coronavirus genus and is related to other coronaviruses such as SARS-CoV and MERS [ 1 , 2 ]. The virus is highly infectious and transmissible, but has a lower mortality rate than SARS-CoV or MERS [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Development and validation of viral load assays to quantitate SARS-CoV-2

Bland

Kavanaugh

Hong

et al. 2021

Journal of Virological Methods

View full text Add to dashboard Cite

SARS-CoV-2 has infected more than 30 million persons throughout the world. A subset of patients suffer serious consequences that require hospitalization and ventilator support. Current tests for SARS-CoV-2 generate qualitative results and are vital to make a diagnosis of the infection. However, they are not helpful to follow changes in viral loads after diagnosis. The ability to quantitatively assess viral levels is necessary to determine the effectiveness of therapy with anti-viral or immune agents. Viral load analysis is also necessary to determine the replicative potential of strains with different mutations, emergence of resistance to anti-viral agents and the stability of viral nucleic acid and degree of RT-PCR inhibition in different types of collection media. Quantitative viral load analysis in body fluids, plasma and tissue may be helpful to determine the effects of the infection in various organ systems. To address these needs, we developed two assays to quantitate SARS-CoV-2. The assays target either the S or E genes in the virus, produce comparable viral load results, are highly sensitive and specific and have a wide range of quantitation. We believe that these assays will be helpful to manage the clinical course of infected patients and may also help to better understand the biology of infection with SARS-CoV-2.

show abstract

A Comprehensive Updated Review on SARS‐CoV‐2 and COVID‐19

Cited by 17 publications

References 186 publications

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

A Comprehensive Review of Tocilizumab in COVID‐19 Acute Respiratory Distress Syndrome

Impact of lockdown for SARS-CoV-2 (COVID-19) on surgical site infection rates: a monocentric observational cohort study

Development and validation of viral load assays to quantitate SARS-CoV-2

Contact Info

Product

Resources

About